News about 'TB News'

Click here to read full report. The 2012 Millennium Development Report was just released highlighting progress made to date. Great strides have been made in HIV and TB from the year 1990 (see below). The Global Plan to Stop TB issued by the Stop TB Partnership is set within the context of the...

Press Release: The Africa Coalition on Tuberculosis (ACT!), whose inception was the result of a Declaration made in Washington, DC, USA in March 2012, kicked off activities at a week-long planning meeting in June in Tirano, Italy. Founding members of the coalition include tuberculosis (TB)...

Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet . The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than...

Structure of Bedaquiline This week it was announced the Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for their drug Bedaquiline (a.k.a. TMC-207). For additional information on...

The Stop TB Partnership made two exciting announcements today: 1. US$ 40 million committed to roll-out of Xpert The executive board of UNITAID today approved funding of US$ 30 million to scale up access to Xpert MTB/RIF, and reduce the cost of its use. In addition, the Stop TB Partnership’s TB...

Delamanid (OPC-67683) This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine ...

For this week’s update, we highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Dooley KE, Mitnick C, Degroote MA, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N,...

World TB Day Congressional Briefing Tuberculosis – We Can Beat this Global Killer Wednesday, March 21, 2012 A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Special areas...

The latest news from the Stop TB Partnership. You may also download a .pdf version by clicking here . WORLD TB DAY NEWS Childhood tuberculosis neglected, despite available remedies TB often goes undiagnosed in children because they lack access to care, or because health workers don’t recognize the...

This week, we are highlighting two articles published online in the Journal of Infectious Diseases in March. The first article by Coxon, et al., looks at the benefits and limitations of the two main approaches to compound discovery for TB, target-based and phenotypic-based. The second article by...

Click here to access publication. The WGND Strategic Plan 2011-2015 is an update of the “New Drugs” section of the Global Plan to Stop TB: 2011-2015 . It describes the progress, gaps, and vision of the WGND and the TB drug development field as a whole. Since its inception, the WGND has served as a...

The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved...

Click here to get more info. Saturday, March 24, is officially World TB Day but there has been a stream of activities, publications, news and messages to let the world not forget about this major infectious disease killer that claims millions of lives each year. Events On March 7 and 13, the CORE...

The audience takes in the promise of the NC--002 trial. During the “Cure All: A briefing on the status of the most promising new TB drugs research” sponsored by the Critical Path to New TB Drug Regimens (CPTR) on Monday, March 19, Dr. Mel Spigelman, CEO & President, of TB Alliance announced the...

At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, results on the Thibela TB preventative therapy trial in South Africa gold miners was presented with mixed outcomes. On one hand, the number of cases in miners in the experimental group who screened negative for...